Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer

Table 1 Patients’ demographics

	All, n = 295
Age at diagnosis in yr, mean (min-max)	63.7 (31-84)
Male, n (%)	176 (59.7%)
Primary tumor site, n (%)
Stomach
Body	139 (47.1%)
Antrum	100 (33.9%)
Cardia	33 (11.2%)
Lower esophagus	3 (1%)
Gastroesophageal junction	20 (6.8%)
Lauren classification1, n (%)
Diffuse	61 (21.6%)
Intestinal or mixed	152 (53.9%)
NOS	69 (24.5%)
Differentiation degree2, n (%)
Well differentiated	26 (11.7%)
Moderately differentiated	75 (33.8%)
Poorly differentiated	121 (54.5%)
Blood cell count and blood ratios serum quantification, mean ± SD
Neutrophiles	6103 ± 3354
Lymphocytes	1890 ± 1014
Platelets	268658 ± 92373
Monocytes	585 ± 407
NLR	4.66 ± 7.1
LMR	5.29 ± 9.2
PLR	182.91 ± 148.19
Clinical/imagiological T stage3, n (%)
T1	12 (4.3%)
T2	67 (23.8%)
T3	130 (46.3%)
T4	72 (25.6%)
Clinical/imagiological N stage4, n (%)
Nx	14 (4.8%)
N0	43 (14.7%)
N1	66 (22.5%)
N2	62 (21.2%)
N3	7 (2.4%)
N+	101 34.5%)
PreFLOT cycles, median (min-max)	4 (1-12)
Progressive disease under preFLOT, n (%)	24 (8.1%)
Suspension of preFLOT due to toxicity, n (%)	22 (7.5%)
Waiting time to surgery in wk, median (min-max)	12 (6-33)
Patients submitted to surgery5, n (%)	271 (91.9%)
Total gastrectomy	129 (49%)
Subtotal gastrectomy	121 (46%)
Distal gastrectomy	2 (0.8%)
Esophagectomy	11 (4.1%)
Lymphadenectomy6, n (%)
D1	9 (4%)
D1+	24 (10.6%)
D2	193 (85.4%)
Resection margin7, n (%)
0	249 (95%)
1	13 (5%)
Pathological T stage4, n (%)
T0	40 (14.7%)
Tis	2 (0.7%)
T1	52 (19%)
T2	39 (14.3%)
T3	96 (35.2%)
T4	44 (16.1%)
Pathological N stage4, n (%)
N0	147 (53.8%)
N1	36 (13.2)
N2	48 (17.6%)
N3	42 (15.4%)
Pathological stage regression, n (%)
T stage regression8	126 (46.5%)
N stage regression9	156 (57.6%)
Post-surgery tumor staging status, n (%)
Tumor downstaging	161 (61%)
No response	53 (20.1%)
Tumor upstaging	50 (18.9%)
TRG10, n (%)
Complete tumor regression	48 (20.1%)
Partial/incomplete tumor regression	111 (46.4%)
No evidence of regression	80 (33.5%)
Mortality status at the end of study time, n (%)
Dead	62 (21%)
Alive	233 (79%)

¹13 missing data.

²73 missing data.

³14 missing data.

⁴22 missing data.

⁵8 missing data.

⁶45 missing data.

⁷9 missing data.

⁸17 missing data.

⁹9 missing data.

¹⁰56 missing data.

FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; NOS: Nitric oxide synthase; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; SD: Standard deviation; TRG: Tumor regression grade.